Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia

Not Applicable

Recruiting

• Conditions: Herpes Zoster (HZ); Post Herpetic Neuralgia (PHN)
• Interventions: Drug: Pregabalin; Drug: Lacosamide

• Registration Number: NCT06969417
• Lead Sponsor: CMH Kharian Medical College

Brief Summary

Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and/or evoked. PHN is likely to interfere with sleep and daily activities.

Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.

Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-04-10
• Status Verified: 2025-05
• Study First Submitted: 2025-05-05
• Study First Submitted QC: 2025-05-12
• Study First Posted: 2025-05-13
• Last Update Submitted: 2025-05-13
• Last Update Posted: 2025-05-14
• Primary Completion: 2025-07-31
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Diagnosed cases of herpes zoster suffering from postherpetic neuralgia
• Ages: 18 to 50
• Both male and female

Exclusion Criteria

• Lack of consent
• Patient already taking pain killers for post herpetic neuralgia
• Patients suffering from other systemic illness

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	Pregabalin	Group A will receive Cap Pregabalin, the first intervention
Group B	Lacosamide	Group B will receive Tab Lacosamide

Primary Outcome Measures

Name	Time	Method
Visual Analog Scale	4 weeks	Pain intensity will be measured before and after treatment with help of Visual Analog Scale.

Trial Locations

Locations (1)

CMH Kharian Medical College; 🇵🇰 Kharan, Punjab, Pakistan